EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Randomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

TROP2 Expression in Salivary Gland Adenoid Cystic Carcinoma ( ACC ) According to Histologic Subtype: Therapeutic Implications

Juliana Mota Siqueira iD, Yoshitsugu Mitani iD, Mario L Marques-Piubelli iD, Camilla Oliveira Hoff, Flavia Bonini, Luana Guimaraes de Sousa, Mutsumi Mitani, Giovanna Lopes Carvalho iD, Fabio Daumas Nunes iD, Leandro Luongo Matos, Shiaw-Yih Lin, Michael T Spiotto und 4 weitere

Journal of Oral Pathology & Medicine · 2025

DOI: 10.1111/jop.70008 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Journal of Oral Pathology & Medicine, 2025. Verfasst von Juliana Mota Siqueira und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic/Head and Neck Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA. Hauptthemen laut MEDLINE: Antigens, Neoplasm, Carcinoma, Adenoid Cystic, Cell Adhesion Molecules, Salivary Gland Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIDCR NIH HHS, NCI NIH HHS, Adenoid Cystic Carcinoma Research Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Adenoid cystic carcinoma (ACC) is a common salivary gland carcinoma with high recurrence and distant metastasis rates. Currently, there is no standard systemic treatment available. TROP2 is a transmembrane glycoprotein involved in the oncogenesis of several tumors that can be therapeutically targeted by a TROP2‐antibody–drug conjugate (ADC). We aimed to characterize TROP2 expression in ACC and assess TROP2 as a potential therapeutic target.

Methods

TROP2 immunohistochemistry was performed in a tissue microarray including 165 ACC of salivary gland. The tumors were grouped according to the histological pattern as non‐solid, solid + non‐solid, or solid. TROP2 protein expression in ACC cell lines was assessed and subjected to drug screening with TROP2‐ADC.

Results

TROP2 expression was high in 59%, moderate in 30%, weak in 8%, and negative in 3% of cases. TROP2 expression was significantly higher in non‐solid compared with solid or solid + non‐solid ( p < 0.001). Notably, TROP2 expression was heterogenous among the dual cellular component, with TROP2 expression identified predominantly in the ductal and not in the myoepithelial cells. In vitro drug screening demonstrated that TROP2‐ADC had selective anti‐tumor effect in TROP2 expressing ACC cells.

Conclusions

TROP2 expression is prevalent in ACC, particularly in the ductal cell component of the non‐solid tumors. The pre‐clinical drug screening findings provide a biological rationale for exploring TROP2 as a therapeutic target in TROP2‐expressing ACC. Trial Registration clinicaltrials.gov : NCT05884320; NCI‐2023‐04260

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antigens, NeoplasmCarcinoma, Adenoid CysticCell Adhesion MoleculesSalivary Gland NeoplasmsAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedBiomarkers, TumorCell Line, TumorImmunoconjugatesImmunohistochemistryTissue Array Analysis

Stichwörter der Autor:innen

ADCSN‐38TROP2adenoid cystic carcinomaantibody–drug conjugateimmunohistochemistrysacituzumab govitecan

Substanzen

Antigens, NeoplasmBiomarkers, TumorCell Adhesion MoleculesImmunoconjugatesTACSTD2 protein, human

Autor:innen und Institutionen

  • Department of Thoracic/Head and Neck Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA.
  • Department of Stomatology, Discipline of Oral and Maxillofacial Pathology, School of Dentistry, University of São Paulo, São Paulo, São Paulo, Brazil.
  • Department of Pathology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA.
  • Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Head and Neck Surgery, Instituto do Câncer do Estado de São Paulo, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (Icesp, HCFMUSP), São Paulo, Brazil.
  • Department of Systems Biology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA.

ORCID-Profile: Juliana Mota Siqueira, Yoshitsugu Mitani, Mario L Marques-Piubelli, Giovanna Lopes Carvalho, Fabio Daumas Nunes

Förderung

  • NIDCR NIH HHS
  • NCI NIH HHS
  • Adenoid Cystic Carcinoma Research Foundation
  • Salivary Gland Tumor Biorepository
  • DeWayne Everage Adenoid Cystic Carcinoma Fund
  • Wold Foundation
  • U.S. Department of Defense
  • Research Histology Core Laboratory

Zitieren

APA

Siqueira, J. M., Mitani, Y., Marques-Piubelli, M. L., Hoff, C. O., Bonini, F., de Sousa, L. G., Mitani, M., Carvalho, G. L., Nunes, F. D., Matos, L. L., Lin, S. Y., Spiotto, M. T., Hanna, E. Y., McGrail, D. J., El-Naggar, A. K., & Ferrarotto, R. (2025). TROP2 Expression in Salivary Gland Adenoid Cystic Carcinoma ( ACC ) According to Histologic Subtype: Therapeutic Implications. Journal of Oral Pathology & Medicine. https://doi.org/10.1111/jop.70008

Vancouver

Siqueira JM, Mitani Y, Marques-Piubelli ML, Hoff CO, Bonini F, de Sousa LG, et al. TROP2 Expression in Salivary Gland Adenoid Cystic Carcinoma ( ACC ) According to Histologic Subtype: Therapeutic Implications. Journal of Oral Pathology & Medicine. 2025. doi:10.1111/jop.70008

BibTeX
@article{Siqueira2025,
  author = {Siqueira, Juliana Mota and Mitani, Yoshitsugu and Marques-Piubelli, Mario L and Hoff, Camilla Oliveira and Bonini, Flavia and de Sousa, Luana Guimaraes and Mitani, Mutsumi and Carvalho, Giovanna Lopes and Nunes, Fabio Daumas and Matos, Leandro Luongo and Lin, Shiaw-Yih and Spiotto, Michael T and Hanna, Ehab Y and McGrail, Daniel J and El-Naggar, Adel K and Ferrarotto, Renata},
  title = {TROP2 Expression in Salivary Gland Adenoid Cystic Carcinoma ( ACC ) According to Histologic Subtype: Therapeutic Implications},
  journal = {Journal of Oral Pathology & Medicine},
  year = {2025},
  doi = {10.1111/jop.70008}
}
Kostenlos starten →